Alternative funding: Disease foundations, govt sources promote available capital
This article was originally published in Scrip
Eager to help firms access capital while government funding is squeezed and venture capitalists are backing away from early-stage technology - and even Big Pharma are cutting research programs - alternative sources of capital are reaching out to the drug development industry.
You may also be interested in...
Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.
Eisai and Biogen, who have an accelerated approval decision pending in the US, said they will seek traditional approvals for lecanemab by Q1 2023 based on positive results from the Phase III Clarity AD trial.